Evidence and Controversies in the treatment of metastatic NSCLC (Ongoing)

Posted On 2020-08-04 02:14:17



The series on “Evidence and Controversies in the treatment of metastatic NSCLC” is edited by Dr. Grace K. Dy, MD, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA. This series is to include a collection of debate-style brief editorials, featuring back-to-back pro/con position from different clinical experts in the field.

Grace K. Dy, MD
Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA

Dr. Grace K. Dy graduated Summa Cum Laude at the top of her graduating medical class at University of Santo Tomas, Philippines. She then completed her internal medicine residency and hematology-oncology fellowship at the world-famous Mayo Clinic at Rochester, MN. She is currently the section chief of thoracic medicine at Roswell Park Comprehensive Cancer Center which was founded in 1898 as the first institution in the world to focus exclusively on cancer research. Her research interests include early phase clinical trials and biomarker development for early cancer diagnosis, theranostics and personalized medicine in thoracic malignancies.

Series outline:

  1. Introduction to the series
  2. ADAURA: The role of adjuvant EGFR TKI and future considerations (pro)
  3. ADAURA: Concerns/controversy regarding adjuvant EGFR TKI and future considerations (con)
  4. CM227/CM9-LA: Evidence supporting ipilimumab-based immunotherapy in the first-line treatment of NSCLC (pro)
  5. CM227/CM9-LA: Concerns/controversy regarding ipilimumab-based immunotherapy in the first-line treatment of NSCLC (con)
  6. Management of acquired resistance to ALK inhibitors: Repeat biopsy to characterize mechanisms of resistance significantly impacts clinical outcomes (pro)
  7. Management of acquired resistance to ALK inhibitors: Repeat biopsy to characterize mechanisms of resistance does not significantly impact clinical outcomes (con)
  8. 1st Line treatment of EGFR/ALK wildtype, PD-L1 TPS 1-49% NSCLC: Evidence supporting treatment with pembrolizumab monotherapy (pro)
  9. 1st line treatment of EGFR/ALK wildtype, PD-L1 TPS 1-49% NSCLC: Concerns with pembrolizumab monotherapy (con)
  10. BRAF V600E mutant, PD-L1 TPS 90% NSCLC: 1st line treatment with targeted therapy 
  11. BRAF V600E mutant, PD-L1 TPS 90% NSCLC: 1st line treatment with Immune checkpoint inhibitors

Disclosure:
The series “Evidence and Controversies in the treatment of metastatic NSCLC” was commissioned by the editorial office, Precision Cancer Medicine without any sponsorship or funding. Grace K. Dy is serving as the unpaid Guest Editor for the series.